SCHEMBL14949504

SCHEMBL14949504

CCOc1cc(Oc2ccc(-c3nnc(Nc4cccc(CF)c4)[nH]3)cc2)nc(N)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.38
MAPK14 Q16539 3/20 0.38
TNNI3K Q59H18 3/20 0.38
PDGFRB P09619 1/20 0.36
KIT P10721 1/20 0.36
PDGFRA P16234 1/20 0.36
CDK11B P21127 1/20 0.36
FLT3 P36888 1/20 0.36
CDKL2 Q92772 1/20 0.36
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NUDT1 P36639 2/20 0.33
MET P08581 2/20 0.31
TEK Q02763 1/20 0.31
BRAF P15056 1/20 0.30
LMNA P02545 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18016751 0.91 PDGFRB (0.37) KDRMAPK14TNNI3KPDGFRBKIT
SCHEMBL14949247 0.88 RAB9A (0.37) KDRTNNI3KPDGFRBKITPDGFRA
SCHEMBL12336276 0.87 PDGFRB (0.49) KDRMAPK14TNNI3KPDGFRBKIT
SCHEMBL14949394 0.85 RAB9A (0.41) KDRMAPK14TNNI3KPDGFRBKIT
SCHEMBL14949248 0.84 SMN1; SMN2 (0.38) RAB9ANPC1ALDH1A1MAPK1SMN1; SMN2
SCHEMBL14949254 0.83 RAB9A (0.38) RAB9ANPC1ALDH1A1MAPK1SMN1; SMN2
SCHEMBL14949246 0.81 SMN1; SMN2 (0.38) RAB9ANPC1ALDH1A1MAPK1SMN1; SMN2
SCHEMBL14949265 0.80 NUDT1 (0.38) RAB9ANPC1ALDH1A1MAPK1SMN1; SMN2
SCHEMBL14949331 0.80 RAB9A (0.39) RAB9ANPC1ALDH1A1MAPK1SMN1; SMN2
SCHEMBL12336527 0.79 PDGFRB (0.41) KDRPDGFRBKITPDGFRACDK11B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 KDR 533/4885MAPK14 90/4885TNNI3K 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.